echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Shanghai Cell Therapy Group completes D1 round of nearly 500 million yuan in financing

    Shanghai Cell Therapy Group completes D1 round of nearly 500 million yuan in financing

    • Last Update: 2021-04-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Shanghai Cell Therapy Group announced that it has successfully completed the D1 round of nearly 500 million yuan in financing.


    fund

    Shanghai Cell Therapy Group was established in 2013 and is dedicated to the cell therapy of tumors.


    In terms of product pipeline, its non-viral vector CD19 CAR-T cell injection (BZ019) is currently the first CAR-T cell therapy drug prepared by a non-viral vector that has been approved to enter the clinic.


    CAR-T

    At present, the cell production center under construction of the company is expected to be completed by the end of April this year.


    In addition, it is worth mentioning that in 2020, Shanghai Mengchao Tumor Hospital, established by Shanghai Cell Therapy Group with an investment of 800 million yuan, will officially operate and become an affiliated hospital of Shanghai University, becoming a clinical research hospital featuring " immunotherapy +".


    Immunity leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.